Kyushu University Academic Staff Educational and Research Activities Database
List of Papers
ICHIRO IEIRI Last modified date:2020.06.24

Professor / Clinical Pharmaceutics / Pharmacy / Kyushu University Hospital

1. Lee N, Maeda K, Fukizawa S, Ieiri I, Tomaru A, Akao H, Takeda K, Iwadare M, Niwa O, Masauji T, Yamane N, Kajinami K, Kusuhara H, Sugiyama Y., Microdosing Clinical Study to Clarify Pharmacokinetic and Pharmacogenetic Characteristics of Atorvastatin in Japanese Hypercholesterolemic Patients, Drug Metab Pharmacokinet., 34, 6, 387-395, 2019.12.
2. Miyake T, Mizuno T, Takehara I, Mochizuki T, Kimura M, Matsuki S, Irie S, Watanabe N, Kato Y, Ieiri I, Maeda K, Ando O, Kusuhara H., Elucidation of N 1-methyladenosine as a Potential Surrogate Biomarker for Drug Interaction Studies Involving Renal Organic Cation Transporters , Drug Metab Dispos., 47, 11, 1270-1280, 2019.11.
3. Higuchi K, Yamashita D, Kashihara Y, Kakara M, Hirota T, Hirakawa M, Ieiri I., Population Pharmacokinetic Analysis of Phenytoin After Intravenous Administration of Fosphenytoin in Adult and Elderly Epileptic Patients , Ther Drug Monit. , 41, 5, 674-680, 2019.10.
4. Takaki H, Ieiri I, Shibuta H, Onozuka D, Hagihara A., The association of tobacco use with prescription of muscle relaxants, benzodiazepines, and opioid analgesics for non-cancer pain., Am J Addict. , 28, 2, 63-70, 2019.06.
5. Mori D, Kashihara Y, Yoshikado T, Kimura M, Hirota T, Matsuki S, Maeda K, Irie S, Ieiri I, Sugiyama Y, Kusuhara H., Effect of OATP1B1 genotypes on plasma concentrations of endogenous OATP1B1 substrates and drugs, and their association in healthy volunteers., Drug Metab Pharmacokinet. 2019 Feb;34(1):78-86. , 34, 1, 78-86, 2019.02.
6. Inoue H, Tamaki Y, Kashihara Y, Muraki S, Kakara M, Hirota T, Ieiri I., Efficacy of DPP-4 inhibitors, GLP-1 analogues, and SGLT2 inhibitors as add-ons to metformin monotherapy in T2DM patients: a model-based meta-analysis., Br J Clin Pharmacol. , 85, 2, 393-402, 2019.06.
7. Kashihara Y, Terao Y, Yoda K, Hirota T, Kubota T, Kimura M, Matsuki S, Hirakawa M, Irie S, Ieiri I., Effects of magnesium oxide on pharmacokinetics of L-dopa/carbidopa and assessment of pharmacodynamic changes by a model-based simulation., Eur J Clin Pharmacol., 75, 3, 351-361, 2019.03, パーキンソン病の患者の多くは便秘を併発することから、治療薬として酸化マグネシウム(MgO)が処方され、治療ガイドラインにおいても第一選択薬とされている。一方、多くの患者は治療にl-dopa/carbidopa(LDCD)を服用している。我々は、MgOがLDの分解を促進し、LDの血中濃度を低下させること、その背景には、MgOがCDを直接分解し、その2次的作用としてLDの分解を促進することをin vitro実験、動物実験、健常成人を対象とした臨床試験により明らかにした。これらの相互作用の臨床的意義をModel-based Meta-analysisの手法を用い検討した結果、LDの効果の減弱の原因になることが示唆された。治療ガイドラインの見直しの必要性が示唆された。.
8. Tamaki Y, Maema K, Kakara M, Fukae M, Kinoshita R, Kashihara Y, Muraki S, Hirota T, Ieiri I., Characterization of changes in HbA1c in patients with and without secondary failure after metformin treatments by a population pharmacodynamic analysis using mixture models., Drug Metab Pharmacokinet. , 33, 6, 264-269, 2018.12.
9. Fujita S, Hirota T, Sakiyama R, Baba M, Ieiri I., Identification of drug transporters contributing to oxaliplatin-induced peripheral neuropathy., J Neurochem. , 148, 3, 373-385, 2019.02.
10. Nakano K, Matoba T, Koga JI, Kashihara Y, Fukae M, Ieiri I, Shiramoto M, Irie S, Kishimoto J, Todaka K, Egashira K., Safety, Tolerability, and Pharmacokinetics of NK-104-NP., Int Heart J. , 59, 5, 1015-1025, 2019.09.
11. Takesue H, Hirota T, Tachimura M, Tokashiki A, Ieiri I., Nucleosome Positioning and Gene Regulation of the SGLT2 Gene in the Renal Proximal Tubular Epithelial Cells., Mol Pharmacol., 94, 3, 953-962, 2018.09.
12. Hirota T, Muraki S, Ieiri I., Clinical Pharmacokinetics of Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer., Clin Pharmacokinet. , 58, 4, 403-420, 2019.05.
13. Takechi T, Kumokawa T, Kato R, Higuchi T, Kaneko T, Ieiri I., Population Pharmacokinetics and Pharmacodynamics of Oral Propranolol in Pediatric Patients With Infantile Hemangioma., J Clin Pharmacol., 58, 10, 1361-1370, 2018.10.
14. Eguchi R, Onozuka D, Ikeda K, Kuroda K, Ieiri I, Hagihara A., The relationship between fine particulate matter (PM2.5) and schizophrenia severity., Int Arch Occup Environ Health., 91, 5, 613-622, 2018.06.
15. Takechi T, Hirota T, Sakai T, Maeda N, Kobayashi D, Ieiri I., Interindividual Differences in the Expression of ATP-Binding Cassette and Solute Carrier Family Transporters in Human Skin: DNA Methylation Regulates Transcriptional Activity of the Human ABCC3 Gene., Drug Metab Dispos., 46, 5, 628-635, 2018.05.
16. Eguchi R, Onozuka D, Ikeda K, Kuroda K, Ieiri I, Hagihara A., Psychological assessment of acute schizophrenia patients who experienced seclusion either alone or in combination with restraint., Int J Psychiatry Med., 53, 3, 171-188, 2018.05.
17. Tanaka T, Hirota T, Ieiri I., Relationship between DNA Methylation in the 5' CpG Island of the SLC47A1 (Multidrug and Toxin Extrusion Protein MATE1) Gene and Interindividual Variability in MATE1 Expression in the Human Liver., Mol Pharmacol. , 93, 1, 1-7, 2018.01.
18. Muraki S, Moriki K, Shigematsu S, Fukae M, Kakara M, Yamashita D, Hirota T, Takane H, Shimada M, Hirakawa M, Ieiri I., Population Pharmacodynamic Analysis of Uric Acid-Lowering Effects of Febuxostat Based on Electronic Medical Records in Two Hospitals., J Clin Pharmacol., 10.1002/jcph.1023. , 2017.10.
19. Miyake T, Mizuno T, Mochizuki T, Kimura M, Matsuki S, Irie S, Ieiri I, Maeda K, Kusuhara H., Involvement of Organic Cation Transporters in the Kinetics of Trimethylamine N-oxide., Pharm Sci., 10.1016/j.xphs.2017.04.067. , 106, 9, 2542-2550, 2017.09.
20. Kashihara Y, Ieiri I, Yoshikado T, Maeda K, Fukae M, Kimura M, Hirota T, Matsuki S, Irie S, Izumi N, Kusuhara H, Sugiyama Y., Small-Dosing Clinical Study: Pharmacokinetic, Pharmacogenomic (SLCO2B1 and ABCG2), and Interaction (Atorvastatin and Grapefruit Juice) Profiles of 5 Probes for OATP2B1 and BCRP., Pharm Sci., 10.1016/j.xphs.2017.03.010. , 106, 9, 2688-2694, 2017.09.
21. Hovelson DH, Xue Z, Zawistowski M, Ehm MG, Harris EC, Stocker SL, Gross AS, Jang IJ, Ieiri I, Lee JE, Cardon LR, Chissoe SL, Abecasis G, Nelson MR., Characterization of ADME gene variation in 21 populations by exome sequencing., Pharmacogenet Genomics., 10.1097/FPC.0000000000000260., 27, 3, 89-100, 2017.05.
22. 家入 一郎, Population pharmacokinetic-pharmacodynamic modeling and model-based prediction of docetaxel-induced neutropenia in Japanese patients with non-small cell lung cancer., Cancer Chemother Pharmacol. , 78, 5, 1013-1023, 2016.11.
23. 家入 一郎, Circulating intestine-derived exosomal miR-328 in plasma, a possible biomarker for estimating BCRP function in the human intestines., Sci Rep. , 6, 32299, 2016.08, A variant in the breast cancer resistance protein (BCRP) gene, 421C> A is a useful biomarker for describing large inter-individual differences in the pharmacokinetics of sulfasalazine (SASP), a BCRP substrate. However, large intra-genotypic variability still exists in spite of the incorporation of this variant into the pharmacokinetics of SASP. Since miR-328 negatively regulates BCRP expression in human tissues, we hypothesized that exosomal miR-328 in plasma, which leaks from the intestines, is a possible biomarker for estimating BCRP activity in the human intestines. We established an immunoprecipitation-based quantitative method for circulating intestine-derived miR-328 in plasma using an anti-glycoprotein A33 antibody. A clinical study was conducted with an open-label, non-randomized, and single-arm design involving 33 healthy participants. Intestine-derived exosomal miR-328 levels positively correlated (P < 0.05) with SASP AUC0-48, suggesting that subjects with high miR-328 levels have low intestinal BCRP activity, resulting in the high AUC of SASP. Circulating intestine-derived exosomal miR-328 in plasma has potential as a possible biomarker for estimating BCRP function in the human intestines..
24. 家入 一郎, Clarification of the mechanism of clopidogrel-mediated drug-drug interaction in a clinical cassette small-dose study and its prediction based on in vitro information., Drug Metab Dispos. , 2016.09.
25. 家入 一郎, Population pharmacodynamic analysis of hemoglobin A1c-lowering effects by adding treatment of DPP-4 inhibitors (sitagliptin) in type 2 diabetes mellitus patients based on electronic medical records., J Diabetes Complications., 30, 7, 1282-1286, 2016.09.
26. 家入 一郎, Drug-drug interactions that interfere with statin metabolism., Expert Opin Drug Metab Toxicol., 11, 9, 1453-1457, 2015.11.
27. 家入 一郎, Effects of multiple-dose rifampicin 450 mg on the pharmacokinetics of fexofenadine enantiomers in japanese volunteers, J Clin Pharmacy Ther, 40, 98-103, 2015.10.
28. 家入 一郎, Sulfasalazine disposition in a subject with 376C>T (nonsense mutation) and 421C>A variants in the ABCG2 gene., Br J Clin Pharmacol., 80, 5, 1236-1237, 2015.11.
29. 家入 一郎, The change of pharmacokinetics of fexofenadine enantiomers through the single and simultaneous grapefruit juice ingestion., Drug Metab Pharmacokinet., 30, 5, 352-257, 2015.10.
30. 家入 一郎, Statin inhibits the expression of secretory phospholipase A2 and subsequent monocyte chemoattractant protein-1 in human endothelial cells., J Cardiovasc Pharmacol., 64, 6, 489-496, 2014.12.
31. 家入 一郎, Addition of bevacizumab enhances antitumor activity of erlotinib against non-small cell lung cancer xenografts depending on VEGF expression., Cancer Chemother Pharmacol. , 74, 6, 1297-1305, 2014.12.
32. 家入 一郎, Neonatal Dubin-Johnson syndrome: novel compound heterozygous mutation in the ABCC2 gene., Pediatr Int., 56, 5, e62-e64, 2014.10.
33. 家入 一郎, Effects of multiple-dose rifampicin 450 mg on the pharmacokinetics of fexofenadine enantiomers in Japanese volunteers., J Clin Pharm Ther. , 40, 1, 98-103, 2014.09.
34. 家入 一郎, Korean, Japanese, and Chinese populations featured similar genes encoding drug-metabolizing enzymes and transporters: a DMET Plus microarray assessment., Pharmacogenet Genomics, 2014.07.
35. 家入 一郎, Identification and functional characterization of novel nonsynonymous variants in the human multidrug and toxin extrusion 2-k., Drug Metab Dispos, 42, 9, 1432-1437, 2014.09.
36. 家入 一郎, Effects of one-time apple juice ingestion on the pharmacokinetics of fexofenadine enantiomers., Eur J Clin Pharmacol, 70, 9, 1087-1095, 2014.09.
37. 家入 一郎, Population pharmacodynamic analysis of LDL-cholesterol lowering effects by statins and co-medications based on electronic medical records., Br J Clin Pharmacol, 2014.04.
38. 家入 一郎, Influences of artificial heart-lung machine operation on the binding sites of albumin: possibility of an effective administration plan., Int J Artif Organs, 37, 2, 99-108, 2014.02.
39. 家入 一郎, Modeling and simulation of bone mineral density response from a phase 2 study of ONO-5334, a new cathepsin K inhibitor, to support dose selection in osteoporosis., J Clin Pharmacol, 54, 8, 937-948, 2014.08.
40. 家入 一郎, Mechanism of the 24-hour rhythm of tumor necrosis factor-alpha formed by onset of rheumatoid arthritis., Chronobiol Int., 31, 4, 564-571, 2014.05.
41. 家入 一郎, Clinical impact of genetic variants of drug transporters in different ethnic groups within and across regions., Pharmacogenomics., 14, 4, 1745-1764, 2013.11.
42. 家入 一郎, Association between DNA methylation in the miR-328 5'-flanking region and inter-individual differences in miR-328 and BCRP expression in human placenta., PLoS One. , 21, 8, e72906, 2013.08.
43. 家入 一郎, MicroRNA-433 negatively regulates the expression of thymidylate synthase (TYMS) responsible for 5-fluorouracil sensitivity in HeLa cells., BMC Cancer, 13, 1, 369, 2013.08.
44. 家入 一郎, MicroRNA-433 negatively regulates the expression of thymidylate synthase (TYMS) responsible for 5-fluorouracil sensitivity in HeLa cells., BMC Cancer, 13, 1, 369, 2013.08.
45. 家入 一郎, Direct and rapid genotyping of SLCO1B1 388A>G and 521T>C in human blood specimens using the SmartAmp-2 method., AAPS J, 15, 2, 618-622, 2013.03.
46. 家入 一郎, Mechanisms of pharmacokinetic enhancement between ritonavir and saquinavir; micro/small dosing tests using midazolam (CYP3A4), fexofenadine (p-glycoprotein), and pravastatin (OATP1B1) as probe drugs., J Clin Pharmacol, 53, 6, 654-661, 2013.06.
47. 家入 一郎, Role of Methotrexate Polyglutamation and Reduced Folate Carrier 1 (RFC1) Gene Polymorphisms in Clinical Assessment Indexes., Drug Metab Pharmacokinet, 28, 5, 442-445, 2013.10.
48. ICHIRO IEIRI, M. Fukaw, K. Maeda, Y. Suguyama, Pharmacogenomic/pharmacokinetic assessment of a four-probe cocktail for CYPs and OATPs following oral microdosing., Int J Clin Pharmacol Ther., 10.5414/CP201763., 50, 10, 689-700, 2012.10.
49. ICHIRO IEIRI, K. Sonoki, M. Iwase, S. Ohdo, Telmisartan and N-acetylcysteine suppress group V secretory phospholipase A2 expression in TNFα-stimulated human endothelial cells and reduce associated atherogenicity., J Cardiovasc Pharmacol., 10.1097/FJC.0b013e3182646ccc., 60, 4, 367-374, 2012.10.
50. ICHIRO IEIRI, S. Endo, A. Fukuhori, S. Tokuhiro, Association study of genetic polymorphisms of drug transporters, SLCO1B1, SLCO1B3 and ABCC2, in African-Americans, Hispanics and Caucasians and olmesartan exposure., J Hum Genet., 10.1038/jhg.2012.63. , 57, 8, 531-544, 2012.08.
51. ICHIRO IEIRI, H. Jeon, IJ. Jang, KS. Lin, Apple juice greatly reduces systemic exposure to atenolol., Br J Clin Pharmacol. , 10.1111/j.1365-2125.2012.04324.x., 75, 1, 172-179, 2013.01.
52. ICHIRO IEIRI, K.Kato, H.Kusuhara, Y. Sugiyama, Association of multidrug resistance-associated protein 2 single nucleotide polymorphism rs12762549 with the basal plasma levels of phase II metabolites of isoflavonoids in healthy Japanese individuals., Pharmacogenet Genomics., 10.1097/FPC.0b013e3283517012., 22, 5, 344-354, 2012.05.
53. ICHIRO IEIRI, Y. Date, Y. Nishibatake, Takeshi Hirota, Dihydropyrimidine dehydrogenase (DPD) expression is negatively regulated by certain microRNAs in human lung tissues., Lung Cancer, 10.1016/j.lungcan.2011.12.018. , 166, 6, 1793-1803, 2012.07.
54. Kusuhara H, Furuie H, Inano A, Sunagawa A, Yamada S, Wu C, Fukizawa S, Morimoto N, Ieiri I, Morishita M, Sumita K, Mayahara H, Fujita T, Maeda K, Sugiyama Y., Pharmacokinetic interaction study of sulfasalazine in healthy subjects and the impact of curcumin as an in vivo inhibitor of BCRP., Br J Pharmacol., 10.1111/j.1476-5381.2012.01887.x., 2012.02.
55. Uenaka K, Nakano M, Willis BA, Friedrich S, Ferguson-Sells L, Dean RA, Ieiri I, Siemers ER., Comparison of pharmacokinetics, pharmacodynamics, safety, and tolerability of the amyloid β monoclonal antibody solanezumab in Japanese and white patients with mild to moderate alzheimer disease., Clin Neuropharmacol., 35, 1, 25-9, 2012.02.
56. Egashira K, Sasaki H, Higuchi S, Ieiri I., Food-drug interaction of tacrolimus with pomelo, ginger, and turmeric juice in rats., Drug Metab Pharmacokinet., 27, 2, 242-7, 2012.04.
57. Ieiri I, Nishimura C, Maeda K, Sasaki T, Kimura M, Chiyoda T, Hirota T, Irie S, Shimizu H, Noguchi T, Yoshida K, Sugiyama Y., Pharmacokinetic and pharmacogenomic profiles of telmisartan after the oral microdose and therapeutic dose., Pharmacogenet Genomics. , 2011 Aug;21(8):495-505, 2011.08.
58. Obayashi K, Tomonari M, Yoshimatsu H, Fukuyama R, Ieiri I, Higuchi S, To H., Dosing time-dependency of the arthritis-inhibiting effect of tacrolimus in mice., J Pharmacol Sci. , 2011 Jul 15;116(3):264-73., 2011.06.
59. Ieiri I, Doi Y, Maeda K, Sasaki T, Kimura M, Hirota T, Chiyoda T, Miyagawa M, Irie S, Iwasaki K, Sugiyama Y., Microdosing Clinical Study: Pharmacokinetic, Pharmacogenomic (SLCO2B1), and Interaction (Grapefruit Juice) Profiles of Celiprolol Following the Oral Microdose and Therapeutic Dose., J Clin Pharmacol., in press, 2011.05.
60. Saito J, Hirota T, Kikunaga N, Otsubo K, Ieiri I., Interindividual differences in placental expression of the SLC22A2 (OCT2) gene: Relationship to epigenetic variations in the 5'-upstream regulatory region., J Pharm Sci. , 2011 Sep;100(9):3875-83., 2011.09.
61. Sasaki T, Hirota T, Ryokai Y, Kobayashi D, Kimura M, Irie S, Higuchi S, Ieiri I., Systematic screening of human ABCC3 polymorphisms and their effects on MRP3 expression and function., Drug Metab Pharmacokinet., in press, 2011.04.
62. To H, Yoshimatsu H, Tomonari M, Ida H, Tsurumoto T, Tsuji Y, Sonemoto E, Shimasaki N, Koyanagi S, Sasaki H, Ieiri I, Higuchi S, Kawakami A, Ueki Y, Eguchi K, Methotrexate chronotherapy is effective against rheumatoid arthritis., Chronobiol Int., 2011 Apr;28(3):267-74., 2011.04.
63. Sasaki T, Takane H, Ogawa K, Isagawa S, Hirota T, Higuchi S, Horii T, Otsubo K, Ieiri I., Population pharmacokinetic and pharmacodynamic analysis of linezolid and a hematologic side effect, thrombocytopenia, in Japanese patients., Antimicrob Agents Chemother. , 2011 May;55(5):1867-73., 2011.05.
64. Yasuniwa Y, Izumi H, Wang KY, Shimajiri S, Sasaguri Y, Kawai K, Kasai H, Shimada T, Miyake K, Kashiwagi E, Hirano G, Kidani A, Akiyama M, Han B, Wu Y, Ieiri I, Higuchi S, Kohno K., Circadian disruption accelerates tumor growth and angio/stromagenesis through a Wnt signaling pathway.
, PLoS One, 2010 Dec 23;5(12):e15330., 2010.12.
65. Tsuda Y, Tatami S, Yamamura N, Tadayasu Y, Sarashina A, Liesenfeld KH, Staab A, Schäfer HG, Ieiri I, Higuchi S., Population pharmacokinetics of tamsulosin hydrochloride in paediatric patients with neuropathic and non-neuropathic bladder., Br J Clin Pharmacol. , 2010 Jul;70(1):88-101.

, 2010.07.
66. Suzuki A, Imanishi Y, Nakano S, Niwa T, Ohmori T, Shirai K, Yoshida S, Furuta N, Takemura M, Ito H, Ieiri I, Seishima M, Ogura S, Itoh Y., Usefulness of serum cystatin C to determine the dose of vancomycin in critically ill patients., J Pharm Pharmacol., 2010 Jul;62(7):901-7.

, 2010.06.
67. Okada R, Ishizu Y, Endo R, Lezhava A, Ieiri I, Kusuhara H, Sugiyama Y, Hayashizaki Y., Direct and rapid genotyping of glutathione-S-transferase M1 and T1 from human blood specimens using the SmartAmp2 method., Drug Metab Dispos., 2010 Oct;38(10):1636-9. Epub 2010 Jul 7.

, 2010.10.
68. Murata Y, Kobayashi D, Imuta N, Haraguchi K, Ieiri I, Nishimura R, Koyama S, Mine K., Effects of the serotonin 1A, 2A, 2C, 3A, and 3B and serotonin transporter gene polymorphisms on the occurrence of paroxetine discontinuation syndrome., J Clin Psychopharmacol., 2010 Feb;30(1):11-7.

, 2010.02.
69. Ide T, Sasaki T, Maeda K, Higuchi S, Sugiyama Y, Ieiri I., Quantitative Population Pharmacokinetic Analysis of Pravastatin Using an Enterohepatic Circulation Model Combined With Pharmacogenomic Information on SLCO1B1 and ABCC2 Polymorphisms., J Clin Pharmacol. , 49(11):1309-17

, 2009.11.
70. Sasaki T, Tabuchi H, Higuchi S, Ieiri I., Warfarin-dosing algorithm based on a population pharmacokinetic/pharmacodynamic model combined with Bayesian forecasting., Pharmacogenomics. , 10(8):1257-66, 2009.08.
71. Ieiri I, Higuchi S, Sugiyama Y., Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs., Expert Opin Drug Metab Toxicol. , 5(7):703-29, 2009.05.
72. Kodama A, To H, Kinoshita T, Ieiri I, Higuchi S., Influence of dosing schedules on toxicity and antitumour effects of combined cisplatin and docetaxel treatment in mice., J Pharm Pharmacol. , 61(5):615-21, 2009.05.
73. Sugahara H, Maebara C, Ohtani H, Handa M, Ando K, Mine K, Kubo C, Ieiri I, Sawada Y. , Effect of smoking and CYP2D6 polymorphisms on the extent of fluvoxamine-alprazolam interaction in patients with psychosomatic disease., Eur J Clin Pharmacol., 65(7):699-704. , 2009.06.
74. Takane H, Kawamoto K, Sasaki T, Moriki K, Moriki K, Kitano H, Higuchi S, Otsubo K, Ieiri I., Life-threatening toxicities in a patient with UGT1A1*6/*28 and SLCO1B1*15/*15 genotypes after irinotecan-based chemotherapy., Cancer Chemother Pharmacol., 63(6):1165-9., 2009.05.
75. Suwannakul S, Ieiri I, Kimura M, Kawabata K, Kusuhara H, Hirota T, Irie S, Sugiyama Y, Higuchi S., Pharmacokinetic interaction between pravastatin and olmesartan in relation to SLCO1B1 polymorphism., J Hum Genet., 53(10):899-904., 2008.06.
76. Yamasaki Y, Ieiri I, Kusuhara H, Sasaki T, Kimura M, Tabuchi H, Ando Y, Irie S, Ware J, Nakai Y, Higuchi S, Sugiyama Y., Pharmacogenetic characterization of sulfasalazine disposition based on NAT2 and ABCG2 (BCRP) gene polymorphisms in humans., Clin Pharmacol Ther. , 84(1):95-103., 2008.06.
77. Takane H, Shikata E, Otsubo K, Higuchi S, Ieiri I., Polymorphism in human organic cation transporters and metformin action., Pharmacogenomics., 9(4):415-22., 2008.04.
78. Hirota T, Takane H, Higuchi S, Ieiri I., Epigenetic regulation of genes encoding drug-metabolizing enzymes and transporters; DNA methylation and other mechanisms., Curr Drug Metab., 9(1):34-8., 2008.01.
79. Ieiri I, Suwannakul S, Maeda K, Uchimaru H, Hashimoto K, Kimura M, Fujino H, Hirano M, Kusuhara H, Irie S, Higuchi S, Sugiyama Y., SLCO1B1 (OATP1B1, an Uptake Transporter) and ABCG2 (BCRP, an Efflux Transporter) Variant Alleles and Pharmacokinetics of Pitavastatin in Healthy Volunteers., Clin Pharmacol Ther. , in press, 2007.04.
80. Shikata E., Ieiri I., Ishiguro S., Takane H., Ohgi S. and Otsubo K., Multiple gene polymorphisms and warfarin sensitivity., Eur J Clin Pharmacol, 62(10):881-3, 2006.10.
81. Shikata E, Yamamoto R, Takane H, Shigemasa C, Ikeda T, Otsubo K, Ieiri I., Human organic cation transporter (OCT1 and OCT2) gene polymorphisms and therapeutic effects of metformin., J Hum Genet. , 52(2):117-22, 2007.02.
82. Takane H., Miyata M., Burioka N., Shigemasa C., Shimizu E., Otsubo K. and Ieiri I., Pharmacogenetic determinants of variability in lipid-lowering response to pravastatin therapy., J Hum Genet, 51; 822-826, 2006.06.
83. Takano A., Kusuhara H., Suhara T., Ieiri I., Morimoto T., Lee YJ., Maeda J., Ikoma Y., Ito H., Suzuki K. and Sugiyama Y., Evaluation of In Vivo P-Glycoprotein Function at the Blood-Brain Barrier Among MDR1 Gene Polymorphisms by Using 11C-Verapamil., J Nucl Med, 47; 1427-1433, 2006.09.
84. Maeda K., Ieiri I., Yasuda K., Fujino A., Fujiwara H., Otsubo K., Hirano M., Watanabe T., Kitamura Y., Kusuhara H. and Sugiyama Y., Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril., Clin Pharmacol Ther, 79; 427-439, 2006.05.
85. Takahashi H., Wilkinson GR., Nutescu EA., Morita T., Scordo MG., Pengo V., Barban M., Padrini R., Ieiri I., Otsubo K., Kashima T., Kimura S., Kijima S. and Echizen H., Different contribution of polymorphism in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans, Pharmacogenetics and Genomics, 16: 101-10., 2006.02.
86. Takane H, Nosaka A, Wakushima H, Hosokawa K, Ieiri I., Rifampin reduces the analgesic effect of transdermal fentanyl.
, Ann Pharmacother. , 39: 2139-40, 2005.12.
87. Ieiri I., Kimura M., Irie S., Urae A., Otsubo K. and Ishizaki T., Interaction magnitude, pharmacokinetics and pharmacodynamics of ticlopidine in relation to CYP2C19 genotypic status., Pharmacogenetics and Genomics, 15; 851-859, 2005.12.
88. Kobayashi D., Ieiri I., Hirota T., Takane H., Maegawa S., Kigawa J., Suzuki H., Nanba E., Oshimura M., Terakawa N., Otsubo K., Mine K. and Sugiyama Y., Functional assessment of ABCG2 (BCRP) gene polymorphisms to protein expression in human placenta., Drug Metab Dispos, 10.1124/dmd.104.001628, 33, 1, 94-101, 33; 94-101, 2005.01.